{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:55:47Z","timestamp":1787774147391,"version":"build-2784847793"},"reference-count":43,"publisher":"The Endocrine Society","issue":"1","funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>In primary aldosteronism (PA), two subtypes are distinguished: aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia (BAH). In general, these are treated by adrenalectomy (ADX) and mineralocorticoid receptor antagonists (MRA), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the effects of surgical treatment and medical treatment on quality of life (QoL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Post hoc comparative effectiveness study within the Subtyping Primary Aldosteronism: A Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan (SPARTACUS) trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Twelve Dutch hospitals and one Polish hospital.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Patients with PA (n = 184).<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>ADX or MRAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome Measures<\/jats:title><jats:p>At baseline and 6-month and 1-year follow-up, we assessed QoL by two validated questionnaires: RAND 36-Item Health Survey 1.0 (RAND SF-36) and European Quality of Life\u20135 Dimensions (EQ-5D).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline, seven of eight RAND SF-36 subscales and both summary scores, as well as three of five EQ-5D dimensions and the visual analog scale, were lower in patients with PA compared with the general population, especially in women. The beneficial effects of ADX were larger than for MRAs for seven RAND SF-36 subscales, both summary scores, and health change. For the EQ-5D, we detected a difference in favor of ADX in two dimensions and the visual analog scale. Most differences in QoL between both treatments exceeded the minimally clinically important difference. After 1 year, almost all QoL measures had normalized for adrenalectomized patients. For patients on medical treatment, most QoL measures had improved but not all to the level of the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both treatments improve QoL in PA, underscoring the importance of identifying these patients. QoL improved more after ADX for suspected APA than after initiation of medical treatment for suspected BAH.<\/jats:p><\/jats:sec>","DOI":"10.1210\/jc.2017-01442","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T12:34:26Z","timestamp":1594989266000},"page":"16-24","source":"Crossref","is-referenced-by-count":128,"title":["Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment"],"prefix":"10.1210","volume":"103","author":[{"given":"Marieke","family":"Velema","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Dekkers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad","family":"Hermus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Timmers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Lenders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"Department of Internal Medicine III, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Groenewoud","sequence":"additional","affiliation":[{"name":"Department of Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Schultze Kool","sequence":"additional","affiliation":[{"name":"Department of Radiology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Langenhuijsen","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Prejbisz","sequence":"additional","affiliation":[{"name":"Department of Hypertension, Institute of Cardiology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert-Jan","family":"van der Wilt","sequence":"additional","affiliation":[{"name":"Department of Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Deinum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SPARTACUS investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"issue":"9","key":"2020071623280135500_B1","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071623280135500_B2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071623280135500_B3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"issue":"5","key":"2020071623280135500_B4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism","volume":"50","author":"Catena","year":"2007","journal-title":"Hypertension"},{"issue":"4","key":"2020071623280135500_B5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.5507\/bp.2014.059","article-title":"Outcomes of adrenalectomy in patients with primary hyperaldosteronism\u2014a single centre experience","volume":"158","author":"Hartmann","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"5","key":"2020071623280135500_B6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/cen.12645","article-title":"Primary aldosteronism: functional histopathology and long-term follow-up after unilateral adrenalectomy","volume":"82","author":"Volpe","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071623280135500_B7","first-page":"1394","article-title":"Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism","volume-title":"Surgery","author":"Wachtel","year":"2014"},{"issue":"3","key":"2020071623280135500_B8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism","volume":"19","author":"Lim","year":"2001","journal-title":"J Hypertens"},{"issue":"8","key":"2020071623280135500_B9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2020071623280135500_B10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ajh.2010.169","article-title":"Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment","volume":"23","author":"Sechi","year":"2010","journal-title":"Am J Hypertens"},{"issue":"1","key":"2020071623280135500_B11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism","volume":"62","author":"Rossi","year":"2013","journal-title":"Hypertension"},{"issue":"4","key":"2020071623280135500_B12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1507\/endocrj.K09E-014","article-title":"Endothelial dysfunction is related to aldosterone excess and raised blood pressure","volume":"56","author":"Tsuchiya","year":"2009","journal-title":"Endocr J"},{"key":"2020071623280135500_B13","volume-title":"Quality of Life Studies: Definitions and Conceptual Issues","author":"Schipper","year":"1990"},{"issue":"3","key":"2020071623280135500_B14","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2009-1763","article-title":"Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism","volume":"95","author":"Sukor","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071623280135500_B15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000093956","article-title":"Psychological aspects of primary aldosteronism","volume":"75","author":"Sonino","year":"2006","journal-title":"Psychother Psychosom"},{"issue":"6","key":"2020071623280135500_B16","doi-asserted-by":"crossref","first-page":"E878","DOI":"10.1210\/jc.2010-2723","article-title":"Psychological assessment of primary aldosteronism: a controlled study","volume":"96","author":"Sonino","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071623280135500_B17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/15622975.2012.665480","article-title":"Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross-sectional study","volume":"15","author":"Apostolopoulou","year":"2012","journal-title":"World J Biol Psychiatry"},{"issue":"9","key":"2020071623280135500_B18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","article-title":"Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial","volume":"4","author":"Dekkers","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2020071623280135500_B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2014.868629","article-title":"2013 ESH\/ESC practice guidelines for the management of arterial hypertension","volume":"23","author":"Mancia","year":"2013","journal-title":"Blood Press"},{"issue":"6","key":"2020071623280135500_B20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2020071623280135500_B21","unstructured":"Zee vd KI , Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND-36: een handleiding. Groningen, the Netherlands: Noordelijk Centrum voor Gezondheidsvraagstukken, NCG; 2012."},{"issue":"3","key":"2020071623280135500_B22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"2020071623280135500_B23","volume-title":"User\u2019s Manual for the SF-36v2 Health Survey","author":"Ware","year":"2007","edition":"2nd ed."},{"issue":"2","key":"2020071623280135500_B24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1524-4733.2009.00596.x","article-title":"Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe","volume":"13","author":"Golicki","year":"2010","journal-title":"Value Health"},{"key":"2020071623280135500_B25","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Measuring Self-Reported Population Health: An International Perspective based on EQ-5D","author":"Szende","year":"2014"},{"issue":"5","key":"2020071623280135500_B26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"1\u20132","key":"2020071623280135500_B27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.20452\/pamw.2638","article-title":"General population reference values for 3-level EQ-5D (EQ-5D-3L) questionnaire in Poland","volume":"125","author":"Golicki","year":"2015","journal-title":"Pol Arch Med Wewn"},{"issue":"9","key":"2020071623280135500_B28","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1210\/jc.2011-0138","article-title":"Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically","volume":"96","author":"Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2020071623280135500_B29","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jpsychires.2012.08.025","article-title":"Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone","volume":"46","author":"K\u00fcnzel","year":"2012","journal-title":"J Psychiatr Res"},{"issue":"3","key":"2020071623280135500_B30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1677\/jme.0.0290319","article-title":"11Beta-hydroxylase and aldosterone synthase expression in fetal rat hippocampal neurons","volume":"29","author":"MacKenzie","year":"2002","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"2020071623280135500_B31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.yhbeh.2008.02.004","article-title":"Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior","volume":"54","author":"Hlavacova","year":"2008","journal-title":"Horm Behav"},{"issue":"5","key":"2020071623280135500_B32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0269881109106955","article-title":"Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release","volume":"24","author":"Hlavacova","year":"2009","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2020071623280135500_B33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14728222.8.1.7","article-title":"Angiotensin as a target for the treatment of Alzheimer\u2019s disease, anxiety and depression","volume":"8","author":"Gard","year":"2005","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"2020071623280135500_B34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.regpep.2004.12.015","article-title":"Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists","volume":"128","author":"Saavedra","year":"2005","journal-title":"Regul Pept"},{"issue":"2","key":"2020071623280135500_B35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","article-title":"Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma","volume":"64","author":"Fernandes-Rosa","year":"2014","journal-title":"Hypertension"},{"issue":"3","key":"2020071623280135500_B36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/SLA.0b013e318165c075","article-title":"The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma","volume":"247","author":"Zarnegar","year":"2008","journal-title":"Ann Surg"},{"issue":"1","key":"2020071623280135500_B37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.surg.2009.11.020","article-title":"Clinical outcome after laparoscopic adrenalectomy for primary hyperaldosteronism: the role of pathology","volume":"148","author":"Tr\u00e9sallet","year":"2010","journal-title":"Surgery"},{"key":"2020071623280135500_B38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"issue":"5","key":"2020071623280135500_B39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/07853890109002089","article-title":"The RAND-36 measure of health-related quality of life","volume":"33","author":"Hays","year":"2001","journal-title":"Ann Med"},{"issue":"6","key":"2020071623280135500_B40","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","article-title":"Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D","volume":"14","author":"Walters","year":"2005","journal-title":"Qual Life Res"},{"issue":"1","key":"2020071623280135500_B41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4187\/respcare.03272","article-title":"Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD","volume":"60","author":"Zanini","year":"2014","journal-title":"Respir Care"},{"issue":"1","key":"2020071623280135500_B42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","article-title":"Quality criteria were proposed for measurement properties of health status questionnaires","volume":"60","author":"Terwee","year":"2007","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2020071623280135500_B43","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/103\/1\/16\/23270199\/jc.2017-01442.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/103\/1\/16\/23270199\/jc.2017-01442.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T06:59:20Z","timestamp":1723273160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/103\/1\/16\/4584209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-01442","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2017,11,1]]}}}